Xeris Pharmaceuticals Stock Performance

XERS Stock  USD 4.82  0.26  5.70%   
On a scale of 0 to 100, Xeris Pharmaceuticals holds a performance score of 16. The firm maintains a market beta of 0.51, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Xeris Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Xeris Pharmaceuticals is expected to be smaller as well. Please check Xeris Pharmaceuticals' sortino ratio, semi variance, as well as the relationship between the Semi Variance and rate of daily change , to make a quick decision on whether Xeris Pharmaceuticals' historical returns will revert.

Risk-Adjusted Performance

Solid

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Xeris Pharmaceuticals are ranked lower than 16 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Xeris Pharmaceuticals unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more

Actual Historical Performance (%)

One Day Return
5.7
Five Day Return
16.99
Year To Date Return
39.31
Ten Year Return
(76.16)
All Time Return
(76.16)
Last Split Factor
1:1
Last Split Date
2021-10-06
1
Disposition of 320 shares by Hecht Beth of Xeris Pharmaceuticals at 3.61 subject to Rule 16b-3
01/03/2025
2
The American Diabetes Association and Xeris Pharmaceuticals Announce National Collaboration to Provide Life-Saving Hypoglycemia Education and Awareness
01/21/2025
3
Disposition of 25842 shares by Johnson Kenneth Erland of Xeris Pharmaceuticals at 3.56 subject to Rule 16b-3
01/31/2025
4
Acquisition by John Shannon of 800000 shares of Xeris Pharmaceuticals subject to Rule 16b-3
02/03/2025
5
Xeris Pharmaceuticals stock hits 52-week high of 3.87 By Investing.com - Investing.com Nigeria
02/18/2025
6
Disposition of 14037 shares by Hecht Beth of Xeris Pharmaceuticals at 2.11 subject to Rule 16b-3
02/21/2025
7
Xeris Appoints Anh Nguyen, MD, MBA as Chief Medical Officer
02/24/2025
8
Insider Trading
02/25/2025
9
Aclaris Therapeutics Reports Q4 Loss, Tops Revenue Estimates
02/27/2025
10
Xeris Biopharma Delivers Record Fourth Quarter and Full-Year 2024 Results and Announces 2025 Guidance
03/06/2025
11
Xeris Biopharma Holdings Inc Q4 2024 Earnings Call Highlights Surpassing Revenue ...
03/07/2025
12
Leerink Partners Issues Positive Forecast for Xeris Biopharma Stock Price
03/10/2025
13
Xeris Pharmaceuticals stock hits 52-week high at 4.69 - Investing.com
03/14/2025
Begin Period Cash Flow71.7 M
  

Xeris Pharmaceuticals Relative Risk vs. Return Landscape

If you would invest  337.00  in Xeris Pharmaceuticals on December 15, 2024 and sell it today you would earn a total of  145.00  from holding Xeris Pharmaceuticals or generate 43.03% return on investment over 90 days. Xeris Pharmaceuticals is currently generating 0.6335% in daily expected returns and assumes 3.0526% risk (volatility on return distribution) over the 90 days horizon. In different words, 27% of stocks are less volatile than Xeris, and 88% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days Xeris Pharmaceuticals is expected to generate 3.41 times more return on investment than the market. However, the company is 3.41 times more volatile than its market benchmark. It trades about 0.21 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly -0.09 per unit of risk.

Xeris Pharmaceuticals Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Xeris Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Xeris Pharmaceuticals, and traders can use it to determine the average amount a Xeris Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = 0.2075

Best PortfolioBest Equity
Good Returns
Average Returns
Small ReturnsXERS
CashSmall RiskAverage RiskHigh RiskHuge Risk
Negative Returns

Estimated Market Risk

 3.05
  actual daily
27
73% of assets are more volatile

Expected Return

 0.63
  actual daily
12
88% of assets have higher returns

Risk-Adjusted Return

 0.21
  actual daily
16
84% of assets perform better
Based on monthly moving average Xeris Pharmaceuticals is performing at about 16% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Xeris Pharmaceuticals by adding it to a well-diversified portfolio.

Xeris Pharmaceuticals Fundamentals Growth

Xeris Stock prices reflect investors' perceptions of the future prospects and financial health of Xeris Pharmaceuticals, and Xeris Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Xeris Stock performance.

About Xeris Pharmaceuticals Performance

Assessing Xeris Pharmaceuticals' fundamental ratios provides investors with valuable insights into Xeris Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Xeris Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Days Of Inventory On Hand 477.41  296.41 
Return On Tangible Assets(0.27)(0.29)
Return On Capital Employed(0.15)(0.16)
Return On Assets(0.17)(0.18)
Return On Equity 1.85  1.94 

Things to note about Xeris Pharmaceuticals performance evaluation

Checking the ongoing alerts about Xeris Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Xeris Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Xeris Pharmaceuticals appears to be risky and price may revert if volatility continues
Xeris Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 203.07 M. Net Loss for the year was (54.84 M) with profit before overhead, payroll, taxes, and interest of 166.24 M.
Xeris Pharmaceuticals currently holds about 111.55 M in cash with (36.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.82.
Xeris Pharmaceuticals has a poor financial position based on the latest SEC disclosures
Latest headline from news.google.com: Xeris Pharmaceuticals stock hits 52-week high at 4.69 - Investing.com
Evaluating Xeris Pharmaceuticals' performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Xeris Pharmaceuticals' stock performance include:
  • Analyzing Xeris Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Xeris Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
  • Examining Xeris Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Xeris Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Xeris Pharmaceuticals' management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Xeris Pharmaceuticals' stock. These opinions can provide insight into Xeris Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Xeris Pharmaceuticals' stock performance is not an exact science, and many factors can impact Xeris Pharmaceuticals' stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Additional Tools for Xeris Stock Analysis

When running Xeris Pharmaceuticals' price analysis, check to measure Xeris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xeris Pharmaceuticals is operating at the current time. Most of Xeris Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Xeris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xeris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Xeris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.